Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update

Maher Hendi; Yiping Mou; Jiemin Lv; Bin Zhang; Xiujun Cai

doi:10.1159/000516405

Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update

Gastrointest Tumors. 2021 Jul 15;8(4):145-152. doi: 10.1159/000516405. eCollection 2021 Oct.

Authors

Maher Hendi¹, Yiping Mou², Jiemin Lv¹, Bin Zhang¹, Xiujun Cai¹

Affiliations

¹ Department of Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Department of Surgery, Zhejiang Provincial Peoples Hospital, Hangzhou, China.

Abstract

Background: Hepatic arterial infusion chemotherapy (HAIC) is one option for treating massive tumors and unresectable hepatocellular carcinoma (HCC). However, there is a lack of remedial treatment after these treatments are ineffective or failed.

Summary: Some studies have discovered that HAIC has greater survival in patients with advanced HCC. A previous study has shown that HAIC is effective in the treatment of advanced HCC, and the data on randomized clinical trials are limited and unclear.

Key message: More clinical trials and research are needed in order to make HAIC a standard and recommended therapy for advanced HCC. Our review focuses on the clinical applications of hepatic artery infusion treatment.

Keywords: FOLFOX; Hepatic artery infusion chemotherapy; Hepatocellular carcinoma; Transarterial chemoembolization.

Publication types

Review